CLS Therapeutics Advocates for Management Overhaul at Xenetic Biosciences (XBIO) Following Stockholder Opposition to Executive Compensation

Key Summary:  On March 18, 2024, CLS Therapeutics, LLC, holding a 14% stake, sent a letter to the board's Corporate Secretary expressing dissatisfaction with the current management.

Market Cap: $7 million | Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform …